In contrast, subsequent large-cohort study by Wang et al. (2023) found no association between DPP4 inhibitors and TB risk, consistent with the findings of a systematic review and meta-analysis by Grenet et al. (2021), which demonstrated no link between DPP4 inhibitor use and respiratory infections risk. This evidence concerns the gene DPP4 and respiratory tract infectious disorder.